OncoMatch/Clinical Trials/NCT06609304
Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
Is NCT06609304 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Axicabtagene Ciloleucel for lymphoma, b-cell.
Treatment: Axicabtagene Ciloleucel — The goal of this clinical trial is to learn if Axicabtagene Ciloleucel (axi-cel) works for consolidation after first-line treatment of high-risk Large B-cell Lymphoma (LBCL). It will also learn about the safety of axi-cel treatment. The main questions it aims to answer are: * Does axi-cel treatment result in prolonged clinical benefit to patients with high-risk LBCL after first-line treatment? * What medical problems do participants have when receiving axi-cel treatment? In this investigator-initiated, single-arm clinical trial, participants will: * Receive atezolizumab treatment at 2.0×10\^6 cells/Kg as a one-time therapy. * Visit the clinic as instructed for checkups and tests.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 positive
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: stem cell transplant
History of stem cell transplantation
Cannot have received: organ transplant
History of organ transplantation
Cannot have received: CAR-T cell therapy
Previous treatment with other modified T-cell therapy
Cannot have received: anti-CD19 therapy
Previous treatment with anti-CD19/CD3 or other anti-CD19 therapies
Cannot have received: immune checkpoint inhibitor
History of any prior systemic immune checkpoint therapy
Cannot have received: cell growth factor or haematopoietic agonist/stimulant
History of short-acting cell growth factors or haematopoietic agonists/stimulants
Lab requirements
Blood counts
adequate bone marrow reserve prior to apheresis
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify